ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki DiseaseEuropean designation follows U.S. FDA Orphan Drug Designation previously granted for the same indicationLandmark KIDCARE trial demonstrated superiority of infliximab over standard retreatment in resistant Kawasaki disease
